Lumos Pharma

Lumos Pharma company information, Employees & Contact Information

Explore related pages

Related company profiles:

Lumos Pharma is a clinical-stage biopharmaceutical company whose mission is to develop new therapies for people with rare diseases, prioritizing its focus where the medical need is high, and the pathophysiology is clear. We are committed to this mission and a strategy that is grounded upon time and cost-efficient drug development to deliver safe and effective therapies to patients. Lumos Pharma’s clinical development program will initially focus on its lead product candidate LUM-201, an oral growth hormone stimulating therapeutic in clinical development for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an alternative to the injections that current PGHD patients endure for many years of treatment. As a key component of our mission, Lumos Pharma is actively seeking strategic partnerships to expand its portfolio of rare disease therapeutic candidates. We leverage our experience, knowledge, and stakeholder collaborations to identify and acquire or in-license novel products for development and commercialization. Driven by a sense of commitment to patients, their families, and the broader community impacted by rare diseases, we seek to be a leading provider of innovative medications that address a multitude of rare diseases.

Company Details

Employees
46
Founded
-
Address
4200 Marathon Blvd, Austin,texas 78756,united States
Phone
512-215-2630
Email
in****@****rma.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Austin, Texas
Looking for a particular Lumos Pharma employee's phone or email?

Lumos Pharma Questions

News

Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures’ Acquisition of Lumos Pharma - Yahoo Finance

Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures’ Acquisition of Lumos Pharma Yahoo Finance

Lumos Pharma Closes $38M Acquisition Deal with Double Point Ventures, Offers Premium Plus CVR Rights - Stock Titan

Lumos Pharma Closes $38M Acquisition Deal with Double Point Ventures, Offers Premium Plus CVR Rights Stock Titan

Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201’s Unique Pulsatile Mechanism of Action - GlobeNewswire

Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201’s Unique Pulsatile Mechanism of Action GlobeNewswire

Scoop: Lumos Labs has FDA nod for ADHD DTx Prismira - pharmaphorum

Scoop: Lumos Labs has FDA nod for ADHD DTx Prismira pharmaphorum

DPV set to acquire Lumos Pharma for $38m - Pharmaceutical Technology

DPV set to acquire Lumos Pharma for $38m Pharmaceutical Technology

Lumos Pharma Completes Merger and Delisting Process - Nasdaq

Lumos Pharma Completes Merger and Delisting Process Nasdaq

Taking aim at injectables, Lumos to advance oral growth hormone therapy into pivotal studies - FirstWord Pharma

Taking aim at injectables, Lumos to advance oral growth hormone therapy into pivotal studies FirstWord Pharma

Novo heads to regulators after Sogroya matches predecessor Norditropin in 3 pediatric growth disorders - Fierce Pharma

Novo heads to regulators after Sogroya matches predecessor Norditropin in 3 pediatric growth disorders Fierce Pharma

2025 Texas BioLife Summit - Wilson Sonsini

2025 Texas BioLife Summit Wilson Sonsini

Lumos Pharma Enters into Definitive Merger Agreement with Double Point Ventures to Go Private via a Tender Offer of $4.25 Cash per Share Plus Contingent Value Rights (CVR) - Yahoo Finance

Lumos Pharma Enters into Definitive Merger Agreement with Double Point Ventures to Go Private via a Tender Offer of $4.25 Cash per Share Plus Contingent Value Rights (CVR) Yahoo Finance

Bruker launches infrared imaging microscope for pharma and life science research - News-Medical

Bruker launches infrared imaging microscope for pharma and life science research News-Medical

LUM-201 phase 2 data for PGHD with Andrew Dauber, MD, MMSc - Contemporary Pediatrics

LUM-201 phase 2 data for PGHD with Andrew Dauber, MD, MMSc Contemporary Pediatrics

NewLink Genetics and Lumos Pharma to Form Biopharma Company - Investing News Network

NewLink Genetics and Lumos Pharma to Form Biopharma Company Investing News Network

Bruker Launches Infrared Imaging Microscope for Pharma and Life Science Research - Business Wire

Bruker Launches Infrared Imaging Microscope for Pharma and Life Science Research Business Wire

Lumos stock jumps as phase 2 results bring first oral growth hormone drug closer to market - Fierce Biotech

Lumos stock jumps as phase 2 results bring first oral growth hormone drug closer to market Fierce Biotech

Lumos' oral growth hormone drug falls short of Novo's injectable incumbent at interim analysis - Fierce Pharma

Lumos' oral growth hormone drug falls short of Novo's injectable incumbent at interim analysis Fierce Pharma

Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update - Yahoo Finance

Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update Yahoo Finance

Growth Hormone Deficiency Market Size to Reach USD 4.5 Billion by 2035, Impelled by Advancements in Early Detection - BioSpace

Growth Hormone Deficiency Market Size to Reach USD 4.5 Billion by 2035, Impelled by Advancements in Early Detection BioSpace

Lumos Pharma Raises $34 Million in Series B Financing - PR Newswire

Lumos Pharma Raises $34 Million in Series B Financing PR Newswire

NewLink’s two-decade run ends in reverse merger, layoffs - BioPharma Dive

NewLink’s two-decade run ends in reverse merger, layoffs BioPharma Dive

A Tale of Two Titans - Ohio University

A Tale of Two Titans Ohio University

Earnings call: Lumos Pharma gears up for Phase 3 trial of LUM-201 - Investing.com India

Earnings call: Lumos Pharma gears up for Phase 3 trial of LUM-201 Investing.com India

Chutes & Ladders—BridgeBio oncology execs take the reins of new spinout - Fierce Biotech

Chutes & Ladders—BridgeBio oncology execs take the reins of new spinout Fierce Biotech

5 Top NASDAQ Biotech and Pharma Stocks: Constellation Leads - Investing News Network

5 Top NASDAQ Biotech and Pharma Stocks: Constellation Leads Investing News Network

Austin's life sciences sector is booming — can it catch up to other top U.S. hubs? - The Business Journals

Austin's life sciences sector is booming — can it catch up to other top U.S. hubs? The Business Journals

Oral medication boosts annualized height velocity among children with GH deficiency - Healio

Oral medication boosts annualized height velocity among children with GH deficiency Healio

Chutes & Ladders—AbbVie's president tacks on COO responsibilities - Fierce Biotech

Chutes & Ladders—AbbVie's president tacks on COO responsibilities Fierce Biotech

New Orleans Life Science Company Names New CEO - Biz New Orleans

New Orleans Life Science Company Names New CEO Biz New Orleans

Robert Suffoletta - Wilson Sonsini

Robert Suffoletta Wilson Sonsini

Aspirin Cuts Liver Fat in Preliminary MASLD Trial - MedPage Today

Aspirin Cuts Liver Fat in Preliminary MASLD Trial MedPage Today

Investigational oral therapy increases height velocity for children with GH deficiency - Healio

Investigational oral therapy increases height velocity for children with GH deficiency Healio

AxoSim appoints Alif Saleh as CEO - Indian Pharma Post

AxoSim appoints Alif Saleh as CEO Indian Pharma Post

A trader says he got insider info from an ex-Goldman Sachs exec while playing drunk squash - markets.businessinsider.com

A trader says he got insider info from an ex-Goldman Sachs exec while playing drunk squash markets.businessinsider.com

Austin's Santé Ventures Closes $250M Life Science Fund - The Business Journals

Austin's Santé Ventures Closes $250M Life Science Fund The Business Journals

Worksport ltd. Announces Production of AL4 Premium Tonneau Cover, Signaling Major Growth Potential - The Manila Times

Worksport ltd. Announces Production of AL4 Premium Tonneau Cover, Signaling Major Growth Potential The Manila Times

Researchers Report Success in Treating Autism Spectrum Disorder - Neuroscience News

Researchers Report Success in Treating Autism Spectrum Disorder Neuroscience News

Top Lumos Pharma Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant